- Home
- FORA vs ACOG Comparison
FORA vs ACOG Comparison
Compare FORA & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- ACOG
- Stock Information
- Founded
- FORA 2014
- ACOG 2000
- Country
- FORA United States
- ACOG Canada
- Employees
- FORA N/A
- ACOG N/A
- Industry
- FORA Computer Software: Prepackaged Software
- ACOG
- Sector
- FORA Technology
- ACOG
- Exchange
- FORA Nasdaq
- ACOG Nasdaq
- Market Cap
- FORA 69.4M
- ACOG 80.3M
- IPO Year
- FORA N/A
- ACOG N/A
- Fundamental
- Price
- FORA $2.31
- ACOG $8.58
- Analyst Decision
- FORA Strong Buy
- ACOG Strong Buy
- Analyst Count
- FORA 1
- ACOG 1
- Target Price
- FORA $5.00
- ACOG $20.00
- AVG Volume (30 Days)
- FORA 76.2K
- ACOG 65.4K
- Earning Date
- FORA 11-12-2025
- ACOG 11-14-2025
- Dividend Yield
- FORA N/A
- ACOG N/A
- EPS Growth
- FORA N/A
- ACOG N/A
- EPS
- FORA N/A
- ACOG N/A
- Revenue
- FORA $25,031,040.00
- ACOG $4,586,341.00
- Revenue This Year
- FORA $47.82
- ACOG N/A
- Revenue Next Year
- FORA $10.11
- ACOG $149.89
- P/E Ratio
- FORA N/A
- ACOG N/A
- Revenue Growth
- FORA 18.59
- ACOG N/A
- 52 Week Low
- FORA $1.64
- ACOG $3.75
- 52 Week High
- FORA $4.03
- ACOG $11.54
- Technical
- Relative Strength Index (RSI)
- FORA 62.63
- ACOG 45.31
- Support Level
- FORA $2.20
- ACOG $8.15
- Resistance Level
- FORA $2.39
- ACOG $10.00
- Average True Range (ATR)
- FORA 0.13
- ACOG 0.56
- MACD
- FORA 0.02
- ACOG 0.01
- Stochastic Oscillator
- FORA 83.33
- ACOG 30.63
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.